GLP-1 medications include commonly used names like Ozempic, Wegovy and Mounjaro, which were although originally designed for diabetes treatment, are now used majorly as weight loss drugs
Consistently, the STEP (Semaglutide Treatment Effect in People with Obesity) trial [22] demonstrated that after 68 weeks of semaglutide therapy in individuals who are overweight or obese, the average weight loss achieved was 14.9%, with 86.4% of participants achieving a reduction of at least 5% from baseline, and 69.1% and 50.5% achieving reductions exceeding 10% and 15%, respectively
These issues can make food less appealing and, in some cases, impair nutrient absorption
But a spokesperson told the Colorado Sun, in 2022, that it opposed the change, arguing the new program could impact drug quality and safety
GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are commonly used to help manage type 2 diabetes and support weight loss